

Reduction of the share premium reserve

In order to facilitate future dividends to the shareholders, the Board of Directors has today decided to propose the ordinary general meeting May 14, 2003, to approve a reduction of the share premium reserve of SEK 291.6 million, of which SEK 35.3 million will be used to cover retained losses, and SEK 256.3 million will be transferred to the company's unrestricted equity. The company's unrestricted equity amounts to SEK -35.3 million. The company's restricted equity amounts to SEK 482.6 million, constituting of SEK 18.4 million in share capital and SEK 464.2 million in share premium reserve. After the reduction, the company's equity will be made up as follows: Share capital of SEK 18.4 million, Share premium reserve of SEK 172.6 million and unrestricted equity of SEK 256.3 million. The transfer to unrestricted equity can not be executed without approval from the district court, which is expected during August, 2003.

Gothenburg Mars 10, 2003

The Board of Directors, Vitrolife AB

For further information, please contact:

Acting CEO, Dr. Magnus Nilsson
Phone: + 46 31 721 80 00
Mobile phone: + 46 708 22 80 61

CFO, Margareta Fischer
Phone: + 46 31 721 80 00
Mobile phone: + 46 708 22 80 13
www.vitrolife.com